Gen-Probe/Chiron file BLA (Biologics License Application) for Procleix Ultrio:
This article was originally published in Clinica
Chiron and strategic partner Gen-Probe have submitted a Biologics License Application (BLA) to the FDA for the blood-screening assay, Procleix Ultrio. The application seeks to add hepatitis B virus (HBV) testing capabilities to the already-approved Procleix HIV-1/HCV assay tool - which simultaneously diagnoses HIV and hepatitis C (HCV). Gen-Probe says Procleix Ultrio has the potential to reduce the window period between infection and detection of HBV by as much as 40% compared with currently-available tests. The product is already approved in Europe.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.